Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1626 1632
This examiner grants 59% of resolved cases
Luisalberto Gonzalez is an examiner in Tech Center 1600 and Art Unit 1624. He has overseen 154 resolved cases, which have resulted in an allowance rate of 59.7 percent. A key data point is the interview lift of 46.8 percent, which shows the change in allowance probability when an interview occurs. This lift is a significant factor for practitioners to consider when compared to the 59.7 percent baseline allowance rate. Engaging in direct communication appears to be an effective strategy for applications assigned to this examiner.
The median days to allowance for these 154 resolved cases is 1057. This duration provides a specific expectation for the time required to reach a grant in Art Unit 1624. The recorded allowance rate indicates the general likelihood of success for filings in this group. Practitioners can use the 1057 days to allowance to manage client expectations regarding the length of the prosecution cycle. The 46.8 percent interview lift suggests that verbal arguments can effectively supplement written responses.
In Tech Center 1600, the prosecution of these cases follows a pattern based on the resolved cases. The 1057 days to allowance is the central tendency for successful outcomes. Applicants should prioritize interviews to capitalize on the interview lift. This data-driven approach allows for more precise planning during the examination process. The recorded allowance rate and interview lift provide a clear picture of the tactical environment.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18575717 | USE OF FLUAZIFOP-P-BUTYL FOR INSECT CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17431499 | USE OF SPIROPIDION | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 19347194 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Final Rejection | SK CHEMICALS Co., Ltd. |
| 17593842 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Non-Final OA | SK CHEMICALS CO., LTD. |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18688014 | SUBSTITUTED S-ALANINATE DERIVATIVES | Non-Final OA | Bayer Aktiengesellschaft |
| 18934169 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 18683106 | COMPOSITIONS FOR ORGAN AND TISSUE PRESERVATION | Non-Final OA | Yale University |
| 18611505 | Substituted Bimane Compounds and Methods of Use Thereof | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18965776 | SOLID FORMS OF ALPHA-1062 GLUCONATE | Non-Final OA | Alpha Cognition Inc. |
| 18703125 | COMPOSITIONS AND METHODS FOR TARGETING GPCR FOR THE PREVENTION AND TREATMENT OF PAIN | Non-Final OA | Duke University |
| 17612989 | PHARMACEUTICAL COMBINATION | Non-Final OA | Agency for Science, Technology and Research |
| 18688126 | MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE | Non-Final OA | The U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 17359714 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
| 18714015 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | Non-Final OA | Arthrosi Therapeutics, Inc. |
| 18453156 | CDK2 DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy